X4 Pharmaceuticals (NASDAQ:XFOR) Receives “Overweight” Rating from Cantor Fitzgerald

X4 Pharmaceuticals (NASDAQ:XFOR)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a research report issued on Wednesday,Benzinga reports. They presently have a $3.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a research report on Friday, February 7th.

X4 Pharmaceuticals Price Performance

Shares of X4 Pharmaceuticals stock traded up $0.01 during trading hours on Wednesday, hitting $0.27. The company’s stock had a trading volume of 405,855 shares, compared to its average volume of 2,840,818. The company has a market cap of $46.37 million, a PE ratio of -2.96 and a beta of 0.39. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. The business has a 50 day moving average price of $0.45 and a two-hundred day moving average price of $0.53. X4 Pharmaceuticals has a 12-month low of $0.24 and a 12-month high of $1.60.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $1.43 million during the quarter, compared to the consensus estimate of $1.07 million. Analysts expect that X4 Pharmaceuticals will post -0.68 earnings per share for the current fiscal year.

Insider Activity at X4 Pharmaceuticals

In related news, CEO Paula Ragan sold 76,473 shares of the firm’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the transaction, the chief executive officer now directly owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. This trade represents a 6.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Adam S. Mostafa sold 74,773 shares of the company’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. Over the last three months, insiders sold 202,663 shares of company stock valued at $91,198. Insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Acorn Capital Advisors LLC bought a new position in shares of X4 Pharmaceuticals in the 4th quarter valued at about $5,363,000. JPMorgan Chase & Co. raised its position in X4 Pharmaceuticals by 501.0% during the fourth quarter. JPMorgan Chase & Co. now owns 459,653 shares of the company’s stock valued at $337,000 after purchasing an additional 383,177 shares during the period. Jane Street Group LLC lifted its stake in shares of X4 Pharmaceuticals by 134.9% in the 4th quarter. Jane Street Group LLC now owns 583,483 shares of the company’s stock valued at $428,000 after purchasing an additional 335,036 shares during the last quarter. Deutsche Bank AG boosted its holdings in shares of X4 Pharmaceuticals by 559.6% in the 4th quarter. Deutsche Bank AG now owns 267,628 shares of the company’s stock worth $195,000 after purchasing an additional 227,051 shares during the period. Finally, State Street Corp boosted its holdings in shares of X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after purchasing an additional 189,105 shares during the period. 72.03% of the stock is owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.